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Background 
Warfarin is a traditional oral anticoagulant for stroke prevention in patients with Non Valvular Atrial 
Fibrillation (NVAF). The novel oral anticoagulants (NOACs), firstly dabigatran (directly targeting the 
enzymatic activity of thrombin) and then rivaroxaban, apixaban and edoxaban (targeting the enzymatic 
activity of factor Xa), have been approved for use in patients with NAVF. Although several studies have 
reported the possible association between warfarin and an increased risk of osteoporotic fracture (1-4), only 
one population-based cohort study was conducted to compare the risk of dabigatran and warfarin, showing a 
lower risk for dabigatran compared with warfarin (5). In addition, a pre-specific analysis of a phase 3 clinical 
trial indicated that edoxaban is a valid alternative to warfarin in patients at increased risk of falling (6). On 
the other hand, no study was conducted on the risk of bone fractures among other direct Xa inhibitors.  
The aim of the present study was to investigate the occurrence of osteoporotic fracture with warfarin, 
dabigatran and direct Xa inhibitors (rivaroxaban and apixaban).  
 
Material and Methods 
A cohort study was performed on administrative databases of the Florence Metropolitan Area. All patients 
treated with oral anticoagulants (OACs) in the year 2015 were included. The first date of OACs prescription 
in the year was considered as the index date. Since the index date, all patients were followed until the 
occurrence of fracture, death, change of OACs treatment, or end of data availability (December 31st, 2015). 
Occurrence of fracture during follow-up was evaluated both from hospital discharge records and emergency 
departments admissions, considering all records with a diagnosis of hip or vertebral fracture in primary or 
secondary diagnosis fields (ICD9-CM code 820.x or 805.x). For each treatment, the rate of fracture/100 
person/year was estimated. Moreover, the Hazard Ratio (HR) of fracture was calculated for patients exposed 
to NOACs (dabigatran or direct Xa inhibitors) compared to warfarin users, using a multivariate cox models 
adjusted for gender, age and pattern of OACs use (incident or non-incident). Edoxaban was not considered in 
this study, since it entered the Italian marked in the second half of 2015 and poor data were available. Data 
analysis was performed using the software STATA version 13; statistical significance was considered with a 
p-value <0.05.  
Results 
Among 16,850 patients treated with OACs, 77.7% used warfarin, 14.5% used direct Xa inhibitos, and 7.6% 
used dabigatran (table 1). Overall, the majority of subjects were men (51.09%), aged 75 or more (67.22), and 
non-incident users (76.71%). Distribution of gender, age and pattern of use significantly differed among 
OACs.  
Table 1: Distribution of general characteristics among users of oral anticoagulant  
 TOTAL 
No. (%) 
WARFARIN 
No. (%) 
DIRECT Xa 
INHIBITORS 
No. (%) 
DABIGATRAN 
No. (%) p-valuea 
Number 16,850 13,091 2,474 1,285  
Gender      
Male 8,608 (51.09) 6,769 (51.71) 1,195 (48.30) 644 (50.12) 
.0027 
Female 8,242 (48.91) 6,322 (48.29) 1,279 (51.70) 641 (49.88) 
Age      
75 years 11,327 (67.22) 8,735 (66.73) 1,718 (69.44) 874 (68.02) <.0001 
<75 years 5,523 (32.78) 4,356 (33.27) 756 (30.56) 411 (31.98)  
Pattern of use      
Incident use 3,925 (23.29) 2,420 (18.49) 1,169 (47.25) 336 (26.15) <.0001 
Non-incident use 12,925 (76.71) 10,671 (81.51) 1,305 (52.75) 949 (73.85)  
a p-value from chi-square test. 
 
For OAC users overall, rate of fractures per 100 person years was 1.58 [1.37 – 1.81] (table 2). Comparing 
NOACs with warfarin, no significant difference emerged in their association with fractures (HR of 1.04 
[0.68 – 1.59] for direct Xa inhibitors; 0.96 [0.56 – 1.63] for dabigatran).  Among warfarin users, the 
occurrence of fractures was significantly higher among female subjects (106/4658.68 events/person years 
and 47/5052.33 events/person years for women and men, respectively; p <0.0001) and patients aged ≥75 
years (19/3309.55 events/person years and 134/6401.46 events/person years for people aged ≥75 and <75, 
respectively; p <0.0001). On the other hand, among users of direct Xa inhibitors or dabigatran, occurrence of 
fractures did not significantly differ among genders or age classes. In all OACs groups, occurrence of 
fractures was comparable among different strata of pattern of use.  
  
 Table 2: Number of Events, Rate and Hazard Ratio, with corresponding 95% confidence Intervals (95% CIs) for 
fractures among users of oral anticoagulants  
 N events / person 
years 
Rate per 100 person 
years [95% CI] 
HRa [95% CI] 
OACs 194/12432.89 1.58 [1.37 – 1.81]  
WARFARIN, overall 153/9711.01 1.58 [1.34 – 1.85] 1 (reference) 
Male 47/5052.33 0.93 [0.70 – 1.24] - 
Female 106/4658.68 2.28 [1.88 – 2.75] - 
p-value <.0001   
≥75 years 134/6401.46 2.09 [1.76 – 2.48] - 
< 75 years 19/3309.55 0.57 [0.37 – 0.90] - 
p-value <.0001   
Incident use 15/1166.83 1.29 [0.78 – 2.13] - 
Non-incident use 138/8544.19 1.62 [1.37 – 1.91] - 
p-value 0.401   
DIRECT Xa INHIBITORS, overall 26/1579.42 1.64 [1.12 – 2.42] 1.04 [0.68 – 1.59] 
Male 9/780.33 1.15 [0.60 – 2.21] 1.28 [0.62 – 2.64] 
Female 17/799.09 2.13 [1.32 – 3.42] 0.94 [0.56 – 1.59] 
p-value 0.137  0.332 
≥75 years 26/1085.51 2.40 [1.63 – 3.52] 1.19 [0.78 – 1.83] 
< 75 years - - - 
p-value    
Incident use 6/508.99 1.18 [0.53 – 2.62] 0.82 [0.31 – 2.12] 
Non-incident use 20/1070.43 1.87 [1.21 – 2.90]  1.12 [0.70 – 1.79] 
p-value 0.329  0.578 
DABIGATRAN, overall 15/969.88  1.55 [0.93 –2.57] 0.96 [0.56 – 1.63] 
Male 5/488.50 1.02 [0.43 – 2.46] 1.17 [0.46 – 2.93] 
Female 10/481.39 2.07 [1.11 – 3.86] 0.88 [0.46 – 1.68] 
p-value 0.200  0.680 
≥75 years 14/658.15 2.13 [1.26 – 3.59] 1.01 [0.58 – 1.75] 
< 75 years 1/311.73 0.32 [0.05 – 2.28] 0.57 [0.08 – 4.25] 
p-value 0.027  0.690 
Incident use 3/156.75 1.91 [0.62 – 5.93] 1.40 [0.41 – 4.86] 
Non-incident use 12/813.13 1.48 [0.84 – 2.60] 0.90 [0.50 – 1.62] 
p-value 0.661  0.669 
a HR calculated using cox models adjusted for gender, age and pattern of use (incident use, yes/no) 
 
 
 
Discussion 
OACs is an inevitable treatment, and the choice of whether using warfarin or one of new OACs is still 
debated. Recently, it has been proposed that osteoporotic fractures could be a crucial factor in the choice 
between dabigatran or warfarin, since an increased risk in the latter compared to the former was reported (5). 
Data from our study do not confirm differences in risk, and provided further evidence of the lack of such 
effect for other OACs (i.e., direct Xa inhibitors). Additional evidence is needed in order to assess the 
importance of considering the possible risk of fractures during the process of choosing and prescribing 
OACs.  Nevertheless, female and elderly subjects appear to have a higher rate of fractures, with a difference 
that was statistically significant with respect to warfarin. 
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